These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38465175)

  • 1. The Safety and Efficacy of the Early Use of Sacubitril/Valsartan After Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.
    - A; Rashid M; Soto CJ; Virk GS; Mekowulu FC; Chaudhari SS; Batool S; Usama M
    Cureus; 2024 Feb; 16(2):e53784. PubMed ID: 38465175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis.
    Kotak S; Hassan W; Mehmood M; Kumar U; Sagreeka F; Karishma F; Kumari P; Pirya F; Saquib J; Iqbal A; Khan AA; Varrassi G; Khatri M; Kumar S
    Cureus; 2023 Oct; 15(10):e46547. PubMed ID: 37933369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sacubitril-valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary percutaneous coronary intervention: a systematic review and meta-analysis.
    Liu Y; Sun Y; Dai W
    Front Pharmacol; 2024; 15():1366035. PubMed ID: 38863978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.
    Gao J; Zhang X; Xu M; Deng S; Chen X
    Front Pharmacol; 2023; 14():1237210. PubMed ID: 37601056
    [No Abstract]   [Full Text] [Related]  

  • 5. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
    Xiong B; Nie D; Qian J; Yao Y; Yang G; Rong S; Zhu Q; Du Y; Jiang Y; Huang J
    ESC Heart Fail; 2021 Dec; 8(6):4852-4862. PubMed ID: 34716749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects and Safety of Sacubitril/Valsartan for Patients with Myocardial Infarction: A Systematic Review and Meta-Analysis.
    Liu L; Ding X; Han Y; Lv J
    J Healthc Eng; 2022; 2022():7840852. PubMed ID: 35035857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.
    Zhang L; Yan K; Zhao H; Shou Y; Chen T; Chen J
    Ann Palliat Med; 2022 Mar; 11(3):1017-1027. PubMed ID: 35365031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis.
    Yang P; Han Y; Lian C; Wu X
    Front Cardiovasc Med; 2022; 9():988117. PubMed ID: 36093128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
    BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
    Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction.
    Zhou X; Zhu H; Zheng Y; Tan X; Tong X
    Front Cardiovasc Med; 2022; 9():953948. PubMed ID: 36304540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction.
    Yang P; Li X; Wang L; Wu X; Wang C; Li T; Wang H
    Front Cardiovasc Med; 2022; 9():1059420. PubMed ID: 36712243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
    Zhao J; Zeng Y; Shen X
    Clin Cardiol; 2021 Oct; 44(10):1354-1359. PubMed ID: 34464468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: A systematic review and meta-analysis.
    Chen WW; Jiang J; Gao J; Zhang XZ; Li YM; Liu YL; Dang HQ
    Clin Cardiol; 2023 Mar; 46(3):296-303. PubMed ID: 36648084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis.
    Mohammad Z; Ahmad J; Sultan A; Penagaluri A; Morin D; Dominic P
    J Cardiovasc Electrophysiol; 2023 Apr; 34(4):1037-1042. PubMed ID: 36871177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
    Ledwidge M; Dodd JD; Ryan F; Sweeney C; McDonald K; Fox R; Shorten E; Zhou S; Watson C; Gallagher J; McVeigh N; Murphy DJ; McDonald K
    JAMA Cardiol; 2023 Apr; 8(4):366-375. PubMed ID: 36884247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Bhattacharjee P; Khan Z
    Cureus; 2023 Nov; 15(11):e48674. PubMed ID: 38090453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.